Concepedia

Author

Caicun Zhou

Shanghai Pulmonary HospitalORCID

Also Known As

C C Zhou, C. Zhou, CAICUN ZHOU, Cai-Cun Zhou, Cai-cun Zhou, CaiCun Zhou, Caicun Zhou, Chenting Zhou, Z Caicun, chunyu zhou

246

Publications

34.4K

Citations

56

H-Index

42

Concepts

All Affiliations

Shanghai Pulmonary HospitalTongji UniversityGuangdong Academy of Medical SciencesGuangdong General HospitalShanghai Chest Hospital
CZ

About

Caicun Zhou is an author at Shanghai Pulmonary Hospital specializing in medicine, lung cancer, and oncology.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Medicine

36

51

17.2K

2

Health Sciences

11

12

2.6K

3

Cell Biology

7

7

485

4

Immunology

6

6

253

5

Molecular Medicine

1

1

24

Caicun Zhou

×

98

Publications

32.3K

Citations

50

H-Index

YearCitations

Osimertinib in Untreated <i>EGFR</i> -Mutated Advanced Non–Small-Cell Lung Cancer

Jean‐Charles Soria, Yuichiro Ohe, Johan Vansteenkiste,

New England Journal of Medicine

2017

5K

Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study

Caicun Zhou, Yi‐Long Wu, Gongyan Chen,

The Lancet Oncology

2011

4K

Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial

Tony Mok, Yi‐Long Wu, Iveta Kudaba,

The Lancet

2019

3.2K

Overall Survival with Osimertinib in Untreated, <i>EGFR</i> -Mutated Advanced NSCLC

Suresh S. Ramalingam, Johan Vansteenkiste, David Planchard,

New England Journal of Medicine

2019

2.7K

Durvalumab plus platinum–etoposide versus platinum–etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial

Luis Paz‐Ares, Mikhail Dvorkin, Yuanbin Chen,

The Lancet

2019

2.1K

Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial

Yi‐Long Wu, Caicun Zhou, Chengping Hu,

The Lancet Oncology

2014

2K

Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials

James Chih‐Hsin Yang, Yi‐Long Wu, Martin Schüler,

The Lancet Oncology

2015

1.6K

Clinical activity of afatinib in patients with advanced non-small-cell lung cancer harbouring uncommon EGFR mutations: a combined post-hoc analysis of LUX-Lung 2, LUX-Lung 3, and LUX-Lung 6

James Chih‐Hsin Yang, Lecia V. Sequist, Sarayut Lucien Geater,

The Lancet Oncology

2015

963

Afatinib versus placebo for patients with advanced, metastatic non-small-cell lung cancer after failure of erlotinib, gefitinib, or both, and one or two lines of chemotherapy (LUX-Lung 1): a phase 2b/3 randomised trial

Vincent A. Miller, Vera Hirsh, Jacques Cadranel,

The Lancet Oncology

2012

950

CNS Response to Osimertinib Versus Standard Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Patients With Untreated <i>EGFR</i>-Mutated Advanced Non–Small-Cell Lung Cancer

Thanyanan Reungwetwattana, Kazuhiko Nakagawa, Byoung Chul Cho,

Journal of Clinical Oncology

2018

763

Page 1